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Abstract Adenosine is a potent extracellular messenger
that is produced in high concentrations under metabolically
unfavourable conditions. Tissue hypoxia, consequent to a
compromised cellular energy status, is followed by the
enhanced breakdown of ATP leading to the release of
adenosine. Through the interaction with A2 and A3
membrane receptors, adenosine is devoted to the restoration
of tissue homeostasis, acting as a retaliatory metabolite.
Several aspects of the immune response have to be taken
into consideration and even though in general it is very
important to dampen inflammation, in some circumstances,
such as the case of cancer, it is also necessary to increase
the activity of immune cells against pathogens. Therefore,
adenosine receptors that are defined as “sensors” of
metabolic changes in the local tissue environment may be
very important targets for modulation of immune responses
and drugs devoted to regulating the adenosinergic system
are promising in different clinical situations.
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Abbreviations
IL interleukin
IFN-+ interferon gamma
TNF-! tumour necrosis factor !
LPS lipopolysaccharide
PHA phytohemagglutinin
NK cells natural killer cells
Introduction
Adenosine is an endogenous purine nucleoside that is
constitutively present at low levels outside the cells but
might dramatically increase its concentrations following
metabolic stress conditions like those induced by hypoxia
or ischaemia. After its release adenosine induces its
biological effects through the interaction with four cell
surface receptors classified by molecular, biochemical and
pharmacological data into four subtypes: A1,A 2A,A 2B and
A3 [1]. Each of these receptors, with the exception of the
A1 subtype, are expressed on human and mouse T
lymphocytes and it appears that their activation represents
a potent endogenous immunosuppressive pathway that
regulates the excessive immune response against potent
external insults. The interest in the immunomodulatory
effects of adenosine arose after the discovery that hereditary
deficiency of the enzyme adenosine deaminase (ADA)
was associated with severe combined immune deficiency
disease (SCID) [2]. ADA converts adenosine to inosine and
deoxyadenosine to deoxyinosine and its activity is greater
in T cells in comparison with B cells or erythrocytes. ADA
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due to the sensitivity of T cells to the accumulation of the
ADA substrates adenosine and 2′-deoxyadenosine. SCID is
a disease characterized by severe lymphocytopenia, affect-
ing both B and T cells, and a marked susceptibility to
infection. The accumulation of adenosine and the activation
of adenosine receptors in T cells may lead to the depletion
of lymphocytes and impairment of their function [3, 4].
Moreover, ADA deficiency in mice causes impairment of
intrathymic T cell development and enhanced thymocyte
apoptosis supporting the hypothesis that adenosine is
responsible for depletion of T cells occurring in ADA
SCID [5]. Indeed, the studies aimed at elucidating the
mechanisms by which the absence of ADA leads to
immunodeficiency first suggested the presence of adeno-
sine receptors on lymphocytes to suppress or dampen the
immune response [6]. Therefore, to understand the patho-
physiological implications of adenosine-triggered effects in
T cells we intend to review the main actions attributed to
adenosine by receptor subtype activation.
Adenosine metabolism and adenosine receptor
activation under physiological and pathological
conditions
Adenosine has several physiological effects through the
interaction with four known adenosine receptors, A1 and A3
that through the interaction with Gi/0 inhibit adenylyl
cyclase activity, and A2A and A2B that increase cAMP
production (a strong immunosuppressive agent) via Gs. In
addition, they can modulate the activity of phospholipase
C, D, A2, cGMP, K
+ and Ca
2+ channels and mitogen-
activated protein kinases (MAPKs) regulating a variety of
cellular effects [1]. It has been suggested that adenosine
receptors act as “sensors” and that extracellular adenosine
acts as a “reporter” of metabolic changes in the local tissue
environment [7]. Adenosine concentrations are normally
regulated through its catabolism by ADA and through
phosphorylation by adenosine kinase. In ADA deficiency
the capacity of adenosine kinase is saturated and adenosine
levels increase from 100–300 nM to 10 μM[ 2], which
could excessively stepwise activate all adenosine receptors.
Moreover, an increase of intracellular adenosine inhibits the
hydrolysis of S-adenosylhomocysteine that is a potent
inhibitor of transmethylation reactions. The lack of ADA
leads also to the accumulation of deoxyadenosine, a
product of DNA degradation, that in contrast to adenosine
does not play a regulatory role in physiological conditions
but determines an increase in deoxyATP that in turn inhibits
DNA synthesis and activates apoptosis suggesting the
possibility that deoxyadenosine itself may also have
pathological effects [2]. Inflammatory tissue conditions
are often associated with a low oxygen tension, or hypoxia,
that is the cause of an associated production of adenosine in
this environment. Therefore, the prevalent activity of
5’nucleotidase over activity of adenosine kinase [8, 9]
occurring in hypoxic conditions is responsible for a
significant adenosine accumulation in sites of tissue injury
[10]. 5′Nucleotidase represents the major enzyme respon-
sible for the extracellular production of adenosine from
AMP and has a critical role in the functional activation of T
cells. Deficiency of 5′nucleotidase activity has been
associated with a number of immunodeficiency diseases,
such as lymphoproliferative disorders and systemic lupus
erythematosus. Abnormal levels of these enzymes may be
associated with an autoimmune pathology [11].
Therefore, under normal conditions adenosine, which is
continuously produced intracellularly and extracellularly
and maintained at low intracellular levels (about 100 nM)
through the metabolic activity exerted by adenosine kinase
and adenosine deaminase, interacts with the high-affinity
A1 and A2A receptor subtypes. In ADA deficiency or in
hypoxic, ischaemic or inflamed conditions, the intracellular
production of adenosine is increased at very high micro-
molar concentrations and transported across cell mem-
branes by specific agents finally leading to the stepwise
activation of all adenosine receptors, including the low-
affinity A2B and A3 subtypes. Adenosine has been
classified as a “retaliatory metabolite” as a consequence of
its ability to mediate an autoregulatory loop, the function of
which is to protect organs from injury following the
initiating stressful stimuli [12, 13]. There are different
mechanisms by which adenosine receptor activation pro-
tects organs. First, it decreases the energy demand of the
tissue, second it can augment oxygen and nutrient supply
through vasodilation, and finally, it regulates the exuberant
immune response to harmful external agents. As basal
adenosine levels have only a marginal influence on the
immune response, ischaemic and inflammatory conditions
represent scenarios in which adenosine levels become high
enough to have significant immunomodulatory and specif-
ically immunosuppressive effects [14].
Adenosine inhibits lymphocyte activation through A2
receptor activation
A body of literature concerning in vitro and in vivo studies
clearly shows the beneficial role of adenosine as an immune
modulator. Activation of T lymphocytes starts from the
recognition of antigen by T cell antigen receptor and CD4
or CD8 coreceptors that initiates a cascade of signalling
events resulting in cytokine secretion, cellular cytotoxicity
and T cell proliferation. The immunosuppressive effects of
adenosine on cytotoxic T lymphocyte (CTL) actions may
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sustained increases in cAMP that, in turn, antagonize T cell
receptor (TCR)-triggered signalling. In particular, adeno-
sine modulates TCR-mediated interleukin (IL)-2 produc-
tion, expression of CD25 and CD69, granule exocytosis,
Fas ligand up-regulation and cell proliferation through the
interaction with A2A receptors [15, 16]. The predominant
expression of A2A receptors, which has been established in
functional assays using selective agonists and antagonists
of A2A receptors, was confirmed by Northern blot studies
[15, 16]. The role of A2A adenosine receptors in the
regulation of the immune response has been investigated by
determining the expression levels of this receptor in
different subsets of functional lymphocytes [17]. The levels
of expression of A2A receptors have been found to be much
higher among T than B cells. T cell subsets are distin-
guished by the expression of TCR coreceptor molecules
CD8+ and CD4+ involved in recognition of class I and
class II major histocompatibility complex, respectively.
More CD4+ than CD8+ T cells express A2A adenosine
receptors. CD8+ T cells are mostly cytotoxic effector cells,
whereas CD4+ cells have been implicated in T-helper cell
activities. Studies of T-helper cell subsets (TH1 and TH2)
reveal that lymphokine-producing cells are much more
likely to express A2A receptors than are cells that do not
produce lymphokines. A possible explanation was that
inhibitory A2A receptors are induced selectively in cells that
produce cytokines, as a means of limiting cytokine release
[17]. In agreement with these results, it has been reported
that activation of CD4+ lymphocytes induced A2A receptor
mRNA expression and resulted in a dose-dependent
inhibition of TCR-mediated interferon gamma (IFN-γ)
production, which is the most important effector molecule
synthesized by Th1 cells [18]. Recently, the effect of
adenosine on IL-2 receptor-associated signalling pathways
was explored in T lymphocytes by Zhang and co-workers
[19]. IL-2 is an immunomodulatory molecule crucial for the
proliferation of activated T cells, and its receptor consists of
three subunits indicated as alpha, beta and gamma.
Signalling through this receptor for the transduction of a
proliferative signal includes Jak1, Jak3 and STAT5. Jak1
and Jak3 activation leads to phosphorylation of tyrosine
residues on IL-2 receptors. Primed by these events the IL-2
complex generates two major proliferative signals. One of
these signals is mediated by the adaptor protein Shc and
activates p42/p44 MAPK and phosphatidylinositol 3-kinase
(PI3K) signalling pathways. The second proliferative signal
transduced by the IL-2 receptor complex involves the
transcription factor STAT5 that after phosphorylation
translocates to the nucleus to control gene expression.
Adenosine, by activating A2A and A2B receptors, inhibits
IL-2-dependent proliferation through inhibition of STAT5
phosphorylation. Because T cells play a major role in
antitumour immunity and considering that adenosine is
highly increased on the microenvironment of solid carci-
nomas, the adenosine-induced defect in IL-2-stimulated
proliferative signalling would be expected to result in a
defective T lymphocyte response in cancer patients and
generally in impaired antitumour immunity (Fig. 1).
Impairment of proliferation has been recently investigated
Fig. 1 Role of adenosine
receptors in the regulation
of immune responses
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inhibits activation of NF-kappa B in response to B cell
antigen receptor (BCR) triggering (Fig. 1). Stimuli known
to enhance 3′,5′-cyclic adenosine monophosphate (cAMP)
are capable of selectively suppressing the activation both of
NF-kB downstream of the BCR and Toll-like receptor 4 in
splenic B lymphocytes. This suppression is reached by
blocking phosphorylation and subsequent degradation of
the inhibitor of NF-kappa B. This suggests that adenosine-
mediated signals represent an important step in the
molecular decision process controlling inflammation versus
anergic immune responses. In this way adenosine might
affect B cell dysfunction in ADA deficiency and may
explain defective B cell proliferation and activation found
in ADA-deficient mice [21]. Convincing evidence of a link
between adenosine receptors and NF-kB activation comes
also from in vivo studies performed in A2A adenosine
receptor knockout (KO) mice. Lipopolysaccharide (LPS),
given to these animals, induced a greater inflammatory
response and a higher binding of NF-kB to nuclear DNA
and consequently a higher cytokine gene transcription in
macrophages [10].
In vivo evidence of the immunosuppressive effects
played by adenosine through A2A receptors
Although it has been demonstrated that adenosine in vitro
acted as an immunosuppressing agent it was not clear, until
genetically modified mice were available, whether its
effects were present also under pathophysiological con-
ditions in vivo. There are many G protein-coupled receptors
that increase cAMP levels showing immunosuppressive
pharmacological effects and that have been considered as
potential anti-inflammatory agents, e.g. catecholamines, pros-
taglandins, dopamine and histamine. However, although
pharmacological evidence underlines their importance as
potential immunosuppressive molecules, there is no real
proof whether their recruitment does occur during physi-
ological control of inflammation in vivo. Such evidence
has been obtained for adenosine A2A receptors. In wild-
type mice, activation of A2A receptors blocked tissue
damage induced by inflammation demonstrating its role in
counteracting inflammation [22, 23]. More recently, the
availability of A2A receptor-deficient mice in models of
acute liver inflammation and sepsis provided the first
conclusive in vivo evidence of A2A receptors playing a
critical role in the suppression of acute inflammation.
Evaluation of T cell-, macrophage- and cytokine-dependent
tissue injury in A2A adenosine receptor-deficient mice
revealed a dramatic increase of local tissue damage and
an increase of proinflammatory cytokines such as tumour
necrosis factor α (TNF-α), IFN-γ and IL-12 in these mice,
but not in wild-type animals [24, 25]. Moreover, low doses
of inflammatory stimuli, which were not damaging in
wild-type animals, were detrimental in terms of liver status
and cytokine levels in knockout mice. These data furnished
the first indisputable demonstration of an in vivo role
played by A2A adenosine receptor in the regulation of
inflammation and underlined a non-redundant role in the
down-regulation of inflammation in vivo. Importantly,
A2A receptors seem to be essential as demonstrated by
the failure of all other anti-inflammatory mechanisms, e.g.
β-adrenergic and prostaglandin receptors, to overcome the
lack of A2A receptors in preventing severe tissue injury.
Experiments performed in thymocytes and T cells from
heterozygous A2A receptor mice showed that there was a
correlation between reduction of A2A receptors and
reduction of cAMP response of the cells after activation
with adenosine and suggesting the lack of A2A spare
receptors in T cells and a lack of compensation by the A2B
receptors [26]. Also the level of apoptosis of thymocytes
from these animals was less pronounced following A2A
activation in comparison to that obtained in wild-type mice.
The expression of other adenosine subtypes like A1,A 2B or
A3 did not compensate for the lack of A2A in lymphoid
organ of deficient mice as suggested by real-time reverse
transcription polymerase chain reaction (RT-PCR) experi-
ments indicating again that in acute models of inflamma-
tion, the A2A receptors play a crucial and non-redundant
role in the protection of tissue from damage derived by
excessive inflammation [27]. It has been also suggested that
in non-exacerbated inflammatory conditions different anti-
inflammatory stimuli, such as other adenosine receptor
subtypes and other anti-inflammatory mediators, may act in
concert to reduce the extent of damage. Therefore, based on
the evidences reported above, the treatment of a series of
diseases such as sepsis, wound healing and rheumatoid
arthritis, might improve following A2A receptor stimula-
tion. Indeed, methotrexate (MTX), which is used for
treatment of rheumatoid arthritis, may mediate its effects
through the release of endogenous adenosine [28]. Even
though its mechanism of action remains unclear, it has been
shown that MTX caused a dose-dependent suppression of T
cell activation and adhesion molecule expression, and this
was not due to lymphocyte apoptosis. The suppression of
intercellular adhesion molecule (ICAM)-1 was adenosine
and folate dependent, suggesting that the suppression of T
cell activation and T cell adhesion molecule expression,
rather than apoptosis, mediated in part by adenosine or
polyglutamated MTX or both, are important mechanisms in
the anti-inflammatory action of MTX [29]. Besides
methotrexate, there is evidence that other therapeutic
agents, such as sulfasalazine and FK-506, could exert their
anti-inflammatory effects by promoting adenosine release
[30, 31].
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stimulation: implications in cancer
The ability of immune cells to recognize and eliminate
tumour cells is fundamental for successful host defence
against cancer. It has been suggested that adenosine, the
concentration of which increases within hypoxic regions of
solid tumours, may interfere with the recognition of tumour
cells by cytolytic effector cells of the immune system [32,
33]. Adoptive immunotherapy with lymphokine-activated
killer (LAK) cells has shown some promise in the treatment
of certain cancers that are unresponsive to conventional
treatment approaches. However, colon adenocarcinomas
tend to respond poorly to LAK therapy, possibly as a result
of tumour-induced immunosuppression. In 1994 Hoskin
and co-workers demonstrated that colon adenocarcinoma
cells inhibited anti-CD3-activated killer cell induction
through the production of a tumour-associated soluble
factor that was distinct from transforming growth factor
beta or prostaglandins [34]. In the same period these
authors indicated adenosine as a possible inhibitor of killer
T cell activation in the microenvironment of solid tumours
[35] and showed that 2-chloroadenosine (2CA), a stable
analogue of adenosine, reduced MHC-unrestricted killing
of P815 tumour target cells by anti-CD3-activated killer
(AK) lymphocytes. 2CA exerted this effect by interfering
with the recognition/adhesion phase of cytolysis. Treatment
with dipyridamole to block cellular uptake of 2CA
increased the inhibition of cytolysis, suggesting the in-
volvement of a cell surface receptor. However, neither
DPCPX nor DMPX, the A1 and A2 receptor antagonists,
respectively, were able to reduce the inhibitory effect of
2CA on AK lymphocyte function. Similarly, the non-
selective A1 and A2 receptor blockers, theophylline and
8-phenyltheophylline, had no effect on 2CA-mediated
inhibition of AK cell activity. These data clearly demon-
strated that 2CA inhibited the cytolytic activity of AK
lymphocytes by interacting with a novel non-A1/A2 cell
surface receptor [36]. Then, MacKenzie and co-workers
[37] evaluated the adhesion of murine spleen-derived anti-
CD3-activated killer (AK) lymphocytes to syngeneic
MCA-38 colon adenocarcinoma cells. Adenosine, in the
presence of the adenosine deaminase inhibitor coformycin,
reduced adhesion by up to 60%. The inhibitory effect of
adenosine was exerted on AK cells and not on the MCA-38
targets and was mediated by cell surface receptors as
adenosine-induced inhibition of adhesion was not abro-
gated following treatment with dipyridamole, a blocker of
adenosine uptake. The agonist potency profile indicated
that the A3 receptor subtype might be responsible for the
inhibition of adhesion. The authors suggested that this
mechanism of immunosuppression, secondary to tissue
hypoxia, may be important in the resistance of colorectal
and other solid cancers to immunotherapy. In addition, the
same authors demonstrated that adenosine exerts a strong
inhibitory effect on the induction of mouse cytotoxic Tcells
[38]. Diminished tumouricidal activity correlated with
reduced expression of mRNAs coding for granzyme B,
perforin, Fas ligand and TNF-related apoptosis-inducing
ligand (TRAIL) (Fig. 1). IL-2 and IFN-γ synthesis by
AK-T cells was also inhibited by adenosine. Also in this
case the inhibitory effect of adenosine on AK-T cell
proliferation was blocked by an A3 receptor antagonist,
suggesting that adenosine acts through A3 receptors to
prevent AK-T cell induction. Tumour-associated adenosine
may act through the same mechanism to impair the
development of tumour-reactive T cells in cancer patients.
Therefore, the suppression of T killer cell function suggests
that adenosine may act as a local immunosuppressant
within the microenvironment of solid tumours. The same
authors reported that adenosine partially inhibits the
interaction of T lymphocytes with tumour cells by blocking
the function of integrin α4β7, which is the major cell
adhesion molecule involved in the adhesion of T cells to
syngeneic MCA-38 adenocarcinoma cells [39]. Importantly,
involvement of α4β7 has also been postulated in leukocyte
localization in inflammatory disorders such as asthma,
intestinal inflammation and rheumatic disorders and may
be regulated by adenosine [40–42]. As adenosine is known
also for its anti-inflammatory effects in addition to its
immunosuppressive actions, it is possible to hypothesize
that adenosine-mediated inhibition of adhesion through
α4β7 found in T cells may be important in a variety of
other inflammatory diseases. Tumour microenvironment
can suppress the function of tumour-infiltrating T cells.
Therefore, the effect of adenosine has been investigated on
the expression of costimulatory molecules by T cells in
resting and activated conditions. One of the most important
costimulatory molecules present on the T cells’ surface are
CD2 and CD28 acting in concert to achieve optimal
costimulation of T lymphocytes during interaction with
antigen-presenting cells. It has been demonstrated that
adenosine interfered with activation-induced expression of
the costimulatory molecules CD2 and CD28 and that their
up-regulation was IL-2 dependent. This effect could not be
attributed to cyclic AMP (cAMP) accumulation resulting
from the stimulation of adenylyl cyclase-coupled adenosine
receptors, even though cAMP at concentrations much
higher than those generated following adenosine stimula-
tion was inhibitory for both CD2 and CD28 expression.
Therefore, it has been proposed that adenosine interferes
with IL-2-dependent T cell expression of costimulatory
molecules via a mechanism that does not involve the
accumulation of intracellular cAMP and through a cell
surface receptor that is coupled to signalling pathways
different from those involving adenylyl cyclase activity,
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adenosine-mediated pathways in tumour-infiltrating T cells,
considering the expression on T cells of adenosine
deaminase in association with CD26 (dipeptidyl aminopep-
tidase), remains to be elucidated [44]. CD26 is a multi-
functional type II cell surface glycoprotein widely
expressed on T, B and natural killer (NK) cells. One of its
functions is that of an adenosine deaminase binding site.
Binding of ADA to CD26 is capable of reducing the local
concentration of adenosine and has an enzymatic role in
protecting T cells from an adenosine-mediated inhibition of
proliferation [44, 45]. Indeed, it has been reported that
adenosine deaminase activity is significantly lower in the
peripheral lymphocytes of cancer patients, suggesting
increased susceptibility of T cells to adenosine-mediated
inhibition within the tumour microenvironment [46].
Moreover, cytotoxic T cells show very low levels of
adenosine deaminase activity, leaving us to hypothesize
that cytotoxic cells would be quite sensitive to the immune
inhibitory effect of adenosine accumulated within tumours.
In this regard, it is relevant to underline that the presence of
the A3 adenosine receptor has been demonstrated in Jurkat
cells, a human leukaemic cell line, where its level is very
high, and in human lymphocytes in which an up-regulation
occurs after T cell activation [47, 48]. In addition to the A3
receptors, antigen activation has been shown to alter the
expression of other adenosine subtypes. For example it has
been reported that A2B receptors are also up-regulated by
phytohemagglutinin (PHA) and/or anti-CD3 in both CD4+
and CD8+ cells [49], and as for A2A subtypes there are
contrasting reports suggesting both that the activation
process increases their expression predominantly in CD8+
and/or CD4+ T cells [17, 18]. These data suggest that
adenosine may stepwise recruit different adenosine recep-
tors following antigen activation. In human lymphocytes,
e.g. A2A and A2B receptors are coexpressed, leading to
synergy in cAMP production [50]; in addition, adenosine
may mediate different signals if each of these receptors is
linked to different effector molecules, as is the case of the
A3 subtype. In contrast to the immunosuppressive role of
adenosine in the environment of solid tumours, recent
findings from in vivo studies of Fishmans’ group report a
stimulatory effect of A3 agonists in the synthesis of IL-12
that is dependent from inhibition of cAMP levels and
protein kinase A expression. This cytokine is a potent
stimulatory agent of NK cells and is a cytotoxic factor that
exerts a potent antitumour effect in vivo. It induces IFN-+
production by activated T and NK cells and augments
cytotoxic activity of these cells via perforin, Fas and
TRAIL-dependent mechanisms. Therefore, it enhances
NK cell activity and probably NK cell-mediated destruction
of tumour cells [51]. This antitumour effect played in
immune cells is in line with other findings of the same
group demonstrating a direct inhibitory action of A3
receptor activation on tumour cell growth [52].
However, in general, it has to be remarked that contrast-
ing results obtained from pharmacological studies may be
explained by the limitations due to the poor selectivity of
agonists and antagonists for adenosine receptors. Recent
data obtained from studies using adenosine receptor KO
mice examined the capability of adenosine and its analogues
to inhibit the ability of lymphokine-activated killer cells
(LAK) to kill tumour cells. This work demonstrated that
adenosine and adenosine A2A ligands suppress the cyto-
toxicity of LAK cells in parallel with their ability to increase
cAMP levels. These effects were produced by interfering
with both perforin-mediated and Fas ligand-mediated killing
pathways. Studies with LAK cells generated from A1 and A3
adenosine receptor KO mice indicated the lack of any
involvement of these adenosine subtypes in the inhibitory
effect exerted by adenosine, whereas LAK cells obtained
from A2 adenosine receptor KO mice were resistant to the
inhibitory effect of this nucleoside. Only very high concen-
trations of the nonselective agonists NECA or CADO
produced mild inhibition of LAK cytotoxicity that were
possibly induced through A2B activation, suggesting a
predominant role of A2A subtype in inhibition of LAK cell
toxicity [53]. Therefore, adenosine has been indicated as an
important intra-tumour factor that inhibits the effector
function of NK and T cells and protects tumours from
immune destruction. Being that these effects are mediated by
A2A receptors, the authors suggest the introduction of A2A
antagonists to increase the efficacy of immunotherapy.
Conclusion and perspectives
The evidences summarized in this review indicate that
adenosine through the interaction with A2 and A3 receptors
plays a crucial role in the regulation of immune cells. The
most important therapeutic implication arising from the
data summarized above is that A2A receptors, proposed as
“natural” brakes of inflammation, appear to represent a
promising pharmacological target to treat a wide variety of
diseases characterized by a strong immunoinflammatory
component. On the other hand, it may be advantageous in
some circumstances to enhance certain aspects of inflam-
mation in order to eliminate the causative agent, as in the
case of cancer. In fact, it has to be remarked that tumour
defence mechanisms are akin to inflammatory processes.
Solid tumours, due to their abnormal vasculature, are often
hypoxic and show increased levels of adenosine that may
be an important mediator of tumour-associated immuno-
suppression. It is likely that killer T cells that may be
recruited against cancer cells fail to act in an effective
manner due to the high level of adenosine in the tumour
114 Purinergic Signalling (2007) 3:109–116microenvironment. Because several of these immunosup-
pressive functions have been attributed to the stimulation of
A3 and A2A receptors, expressed on the surface of T cells,
adenosine antagonists of these subtypes may be potentially
useful in the immunotherapy of cancer.
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